Business Context and Reporting Period
Microchip Technology Incorporated develops and sells embedded control solutions, including microcontrollers, analog and mixed-signal products, FPGAs, memory, timing, connectivity and related technology licenses. This Form 10-K covers the fiscal year ended March 31, 2022, rather than a calendar 2021 fourth quarter. Results are presented under U.S. GAAP and were audited by Ernst & Young LLP with unqualified opinions on the financial statements and internal control over financial reporting.
Key Financial Metrics
| Metric | Fiscal 2022 | Fiscal 2021 | Change |
|---|---|---|---|
| Net sales | $6.821 billion | $5.438 billion | +25.4% |
| Gross profit | $4.450 billion | $3.379 billion | +31.7% |
| Gross margin | 65.2% | 62.1% | +310 basis points |
| Operating income | $1.850 billion | $998.1 million | +85.3% |
| Operating margin | 27.1% | 18.4% | +870 basis points |
| Net income | $1.286 billion | $349.4 million | +268.0% |
| Diluted EPS | $2.27 | $0.65 | +248% |
| Cash flow from operations | $2.843 billion | $1.917 billion | +48.3% |
| Capital expenditures | $370.1 million | $92.6 million | +299.5% |
Fiscal 2022 net sales consisted of $3.815 billion from microcontrollers, $1.939 billion from analog products and $1.067 billion from other products and services. Microcontroller revenue increased 28.8% and analog revenue increased 27.6%. Technology licensing revenue was $122.0 million, compared with $102.9 million in fiscal 2021.
Cash, cash equivalents and short-term investments totaled $319.4 million at March 31, 2022. Total debt principal was $7.84 billion, including $1.40 billion drawn under the $2.75 billion revolving credit facility, $5.60 billion of senior notes and $838.1 million of convertible debt. Net debt carrying value was $7.687 billion. Fixed-rate debt totaled $6.44 billion; management estimated that a 50-basis-point increase in rates would increase annual interest expense by approximately $7.0 million.
Inventory increased to $854.4 million, or 125 days, from $665.0 million, or 112 days. The company expected inventory to reach 128 to 134 days at June 30, 2022. Accounts receivable were $1.073 billion, and distributor inventory declined to 17 days from 22 days.
Material Changes Versus the Prior Comparable Period
- Strong semiconductor demand and price increases drove the 25.4% sales increase. Management could not quantify the separate contribution of pricing, product mix and end-market demand.
- Gross margin improved primarily because fiscal 2021 included $29.6 million of unabsorbed capacity charges, while fiscal 2022 operated above normal capacity. Product mix, higher average gross profit per unit and increased licensing revenue also benefited margins.
- Operating expenses increased, but declined as a percentage of sales. R&D rose 18.3% to $989.1 million, while selling, general and administrative expense rose 17.8% to $718.9 million.
- Amortization of acquired intangible assets declined to $862.5 million from $932.3 million due primarily to accelerated amortization methods. Goodwill was $6.674 billion and net intangible assets were $4.043 billion at year-end.
- Interest expense fell to $257.0 million from $356.9 million, primarily due to debt paydown and lower rates on variable-rate debt. Losses on debt settlements declined to $113.4 million from $299.6 million.
- Operating cash flow increased by $926.2 million, although higher production, materials costs and inventory investment consumed working capital.
- Capital expenditures increased materially to expand manufacturing capacity and research and development equipment. Internal assembly and test capacity increased to approximately 59% and 64%, respectively, from 53% and 57%.
- The company paid $503.8 million in dividends and repurchased approximately 5.6 million shares for $425.6 million. Approximately $3.57 billion remained available under the $4.00 billion repurchase authorization.
Guidance, Outlook, Commentary and Risks
- Management expected supply-chain constraints to persist through calendar 2022 and into calendar 2023. Strong demand continued to exceed available internal and external manufacturing capacity.
- Microchip launched a Preferred Supply Program under which participating customers provide 12 months of non-cancellable and non-reschedulable orders in exchange for prioritized capacity. Management stated that a significant portion of capacity was booked under the program, but the program is not a guarantee of supply and may increase future excess-inventory risk.
- The company intended to invest $450 million to $550 million in equipment and facilities during the following 12 months, funded through cash balances and operating cash flow.
- Management believed existing liquidity, operating cash flow and revolving-credit availability were sufficient for anticipated requirements for at least the next 12 months. Major requirements include debt service, capital expenditures, dividends, repurchases, working capital and taxes.
- The semiconductor business remains exposed to demand cyclicality, pricing pressure, changing product mix, manufacturing yields, capacity utilization, customer order volatility and limited shipment visibility.
- Approximately 60% of fiscal 2022 sales came from products manufactured at outside wafer foundries; third parties performed approximately 41% of assembly and 36% of testing. Capacity limitations, supplier disruptions or cost increases could constrain revenue and margins.
- Approximately 78% of sales were to foreign customers, including approximately 22% to China and 15% to Taiwan. Risks include trade restrictions, tariffs, sanctions, currency movements, geopolitical developments and COVID-19-related disruptions. The company ceased shipments to Russia and Belarus and reported no material financial impact as of the filing date.
- The company faces substantial debt maturities, including $3.4 billion due in fiscal 2024 and $1.7 billion due in fiscal 2025. Refinancing and interest-rate conditions could affect liquidity and borrowing costs.
- Fiscal 2023 tax cash payments could increase significantly because the Tax Cuts and Jobs Act requires capitalization and amortization of U.S. and non-U.S. research and development expenditures beginning in fiscal 2023, absent legislative changes.
- The IRS issued a notice of deficiency covering fiscal 2007 through fiscal 2012, largely involving transfer pricing. Microchip challenged the assessment and believes it has adequate reserves, but an adverse outcome could materially affect financial position, results or cash flows.
- Special charges increased to $29.5 million, including wafer-fabrication restructuring, legal contingencies and facility-exit costs. The company also recorded $3.0 million of intangible-asset impairment and disclosed approximately $100 million of possible but not probable aggregate legal exposure above accrued amounts.
- Pending matters include shareholder and derivative litigation relating to the Microsemi acquisition, a proposed shareholder settlement subject to final court approval, and an arbitration claim involving alleged defective Atmel ASICs used in automotive airbag control units.
Most Important Facts to Verify
- Confirm the reporting period: the filing is for the fiscal year ended March 31, 2022, not a standalone 2021 fourth-quarter filing.
- Reconcile the reported earnings improvement with the effects of pricing, capacity utilization, product mix, debt-settlement losses and tax items.
- Review debt maturities, revolving-credit availability, covenant compliance and the company’s ability to fund $450 million to $550 million of planned capital expenditures while maintaining dividends and repurchases.
- Monitor inventory growth, distributor inventory levels and the Preferred Supply Program for signs of demand normalization or excess inventory.
- Assess dependence on external foundries and contractors, foreign sales, China and Taiwan exposure, and continuing supply-chain constraints.
- Review the IRS transfer-pricing dispute, $804.1 million of unrecognized tax benefits, fiscal 2023 tax-law effects and other tax examinations.
- Evaluate pending litigation, indemnification obligations, restructuring charges and the approximately $100 million of possible but not probable legal exposure disclosed above accrued amounts.
- Consider the impact of acquired intangible amortization, goodwill concentration and future impairment risk on reported earnings and cash generation.